IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 46.2% in the third quarter, HoldingsChannel.com reports. The fund owned 1,845,711 shares of the medical research company’s stock after buying an additional 583,396 shares during the quarter. JPMorgan Chase & Co.’s holdings in IQVIA were worth $437,378,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Canada Pension Plan Investment Board grew its stake in IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after buying an additional 211,653 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in shares of IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. FMR LLC increased its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. Impax Asset Management Group plc lifted its position in IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares during the last quarter. Finally, Legal & General Group Plc grew its position in IQVIA by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after purchasing an additional 11,715 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

NYSE IQV opened at $199.39 on Friday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock’s 50-day moving average price is $205.48 and its two-hundred day moving average price is $222.69. The company has a market cap of $36.19 billion, a PE ratio of 26.17, a PEG ratio of 2.05 and a beta of 1.49. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on IQV shares. Truist Financial cut their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Barclays lowered their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Wednesday, December 11th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.